Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (TDAC) issued 4,657,499 Class A ordinary shares to its Sponsor, TDAC Partners LLC, on June 12, 2026. This issuance resulted from the conversion of an equal number of Class B ordinary shares held by the Sponsor. The conversion did not generate any cash proceeds for the company and did not impact the amount in the trust account or the per-share redemption value of public Class A ordinary shares, which was approximately $10.69.

Translational Development Acquisition Corp. (TDAC) is holding an Extraordinary General Meeting on June 17, 2026, to seek shareholder approval for extending its business combination deadline. The company proposes to extend the deadline by up to twelve one-month periods, from June 24, 2026, to June 24, 2027, to allow sufficient time to complete its previously announced merger with ProLogium Holding Inc. The extension requires monthly payments into the trust account by the sponsor. Public shareholders have the right to redeem their shares by June 15, 2026, if they do not wish to continue their investment.

Translational Development Acquisition Corp. (TDAC) has entered into a definitive business combination agreement with ProLogium Holding Inc., a global leader in solid-state battery innovation. Upon closing, ProLogium will become a publicly listed company named ProLogium Technology, trading on Nasdaq under the ticker symbol PRLG. The transaction values ProLogium at approximately $3.8 billion on a pre-money, net cash-free basis and is expected to fund the scaling of its 4th-generation battery production and the construction of a new gigafactory in Dunkirk, France, supported by a ~€1.4 billion subsidy.

Translational Development Acquisition Corp. (TDAC) reported a net income of $1.33 million for Q1 2026, a decrease from $1.48 million in Q1 2025, with basic and diluted net income per share falling to $0.06 from $0.07. The company's management raised substantial doubt about its ability to continue as a going concern due to liquidity issues and the mandatory liquidation deadline of June 24, 2026, if a business combination is not completed. Cash decreased to $24,630, and the company increased its promissory note from a related party to $500,000 to fund operations.

Translational Development Acquisition Corp. (TDAC) filed an amendment to its 10-K, revising its conclusion regarding the effectiveness of its disclosure controls and procedures. The company now states that these controls were not effective as of December 31, 2025. This amendment also incorporates new certifications from the principal executive and financial officers as mandated by Sections 302 and 906 of the Sarbanes-Oxley Act. Despite the ineffectiveness of disclosure controls, management affirmed that internal control over financial reporting remained effective as of the same date.

Translational Development Acquisition Corp. filed an amendment to its 10-K, primarily to update Item 9A "Controls and Procedures" and include new certifications under the Sarbanes-Oxley Act. Management concluded that the company's disclosure controls and procedures, as well as its internal control over financial reporting, were effective as of December 31, 2025. No material changes in internal control over financial reporting were reported.